Patients with Burkitt's lymphoma who present with high tumor burden, underlying frailty, or baseline laboratory abnormalities — including renal insufficiency or disease-related hyperbilirubinemia — require a modified initial approach. These factors significantly affect treatment tolerability and the risk of early complications.
In cases where patients have high-burden disease, are frail, or present with baseline laboratory abnormalities including renal insufficiency, standard intensive therapy may not be safely initiated immediately. Disease-related hyperbilirubinemia can similarly preclude certain agents, requiring a bridging strategy before escalation.
Management in this setting typically begins with a prephase step aimed at controlled disease debulking and mitigation of the risk of fulminant tumor lysis syndrome — before proceeding to more intensive therapy. The full regimen structure, sequencing, and complete evidence-based details are available in the structured protocol below.
DOI: 10.1182/blood.2019004099
In cases where patients have high-burden disease, are frail, or are presenting with baseline laboratory abnormalities including renal insufficiency, prephase therapy can be implemented to mitigate risk.
In addition, for patients with hyperbilirubinemia related to disease that precludes the administration of anthracyclines or vinca-alkaloids, employing a prephase can be an effective strategy.
Prephase treatment strategies, which typically include the use of prednisone and cyclophosphamide, with or without vincristine, allow for the prevention of fulminant TLS that may be seen with more intensive multiagent therapy.
View source ↗